Literature DB >> 1154366

HL-A8: a genetic link with thyrotoxicosis.

S Whittingham, P J Morris, F I Martin.   

Abstract

The incidence of HL-A8 was significantly increased in 64 Caucasian patients with thyrotoxicosis compared with 700 Australian blood donors (42% versus 24%). No significant correlation was observed between HL-A8 and autoantibodies to thyroid components in thyrotoxic patients; thus the association of HL-A8 must be either with the disease itself, or possibly with immune responses not tested for this study.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1154366     DOI: 10.1111/j.1399-0039.1975.tb00607.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

1.  TSH-receptor antibodies, HLA B8 and thyroid autoantibodies in patients with Graves' disease in therapeutically induced euthyroidism.

Authors:  G Schernthaner; H Ludwig; H Schleusener; R Finke; P Kotulla; W R Mayr
Journal:  Experientia       Date:  1979-10-15

2.  Immunogenetic markers in patients with Graves' disease.

Authors:  E Schifferdecker; P Kühnl; K Schöffling; B Manfras; G Holzberger; W Spielmann; B O Böhm
Journal:  Klin Wochenschr       Date:  1991-04-04

Review 3.  The HLA linkage group and disease susceptibility.

Authors:  J Bertrams; M Spitznas
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1976-07-26

4.  HLA-DR3 and HLA-DR5 confer risk for autoantibody positivity against the thyroperoxidase (mic-TPO) antigen in healthy blood donors.

Authors:  B O Boehm; P Kühnl; C Löliger; U Ketzler-Sasse; G Holzberger; S Seidl; R Bäuerle; E Schifferdecker; K H Usadel
Journal:  Clin Investig       Date:  1993-03

5.  Human lymphocyte antigens (HLA) and Graves' disease in Turkey.

Authors:  Y Orhan; A Azezli; M Carin; F Aral; E Sencer; S Molvalilar
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

6.  Human leukocyte antigen (HLA) in Korean patients with autoimmune thyroid diseases.

Authors:  K B Huh; H C Lee; H M Kim; H R Lee; C S Hong; S Y Lee; H J Choi; K Park; C K Kim
Journal:  Korean J Intern Med       Date:  1986-07       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.